Premium
The Effects of 5‐Azacytidine on the Long‐term Stability of HLA Class I Upregulation
Author(s) -
Hansen Adam,
O'Donnell Robert W
Publication year - 2019
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2019.33.1_supplement.621.5
Subject(s) - downregulation and upregulation , human leukocyte antigen , dna methylation , epigenetics , flow cytometry , vorinostat , immunotherapy , biology , cancer research , histone deacetylase , antigen , microbiology and biotechnology , immune system , histone , immunology , gene expression , genetics , dna , gene
The epigenetic modifiers, such as DNA methylation inhibitors and histone deacetylase inhibitors, 5‐Azacytidine (5‐AzaC) and Vorinostat, have been shown to increase human leukocyte antigen (HLA) expression. The expression of HLA is required for a T‐cell response to detect tumor cells. A lack of HLA expression allows tumor cells to escape immune detection. It has been previously shown that 5‐AzaC is able to upregulate HLA expression in the cell line MDA‐MB‐435. However, the long‐term stability of increased HLA expression, following a transient absence of 5‐AzaC, is not known. Two flasks of MDA‐MB‐435 cells, one being continually treated twice a week with 5‐AzaC at 0.1 μg/mL, and the other, an untreated control flask are being propagated for long periods of time. Periodically the cells are harvested and incubated with control antibodies or the experimental antibodies, Anti‐HLA‐ABC and analyzed via flow cytometry. Our experiments will help determine if the length of 5‐AzaC exposure modifies HLA expression in MDA‐MB‐435 cells. Experimentation on the role of 5‐AzaC is also planned to optimize both the overall upregulation of HLA expression, and the long‐term expression following the removal of 5‐AzaC. Understanding the long‐term stability of HLA upregulation may prove to be beneficial and applicable to cancer immunotherapy, an expanding field of improved cancer treatments. This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .